Ultragenyx Q3 revenue $139M (+42% YoY); Breakthrough Therapy for setrusumab; DTX401 crossover 62% cornstarch reduction

Ultragenyx Pharmaceutical Inc.

2024-Q3 EPS reported -$4.91 revenue$395,353,000

Total revenue $139M, up 42% YoY; Crysvita $98M (+31%), Dojolvi $21M (+29%), Evkeeza $11M.
Net loss $134M ($1.40/share) vs $160M ($2.23) YoY; operating cash burn $67M in Q3.
FY2024 guidance reaffirmed: total revenue $530-550M, Crysvita upper end $375-400M, Dojolvi $75-80M.
Setrusumab (UX143) granted FDA Breakthrough Therapy for osteogenesis imperfecta based on 67% fracture reduction.
DTX401 Phase 3 crossover patients showed 62% mean cornstarch reduction at week 30; BLA submission planned mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.